ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ALX Oncology Holdings Inc. on April 23, 2025. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol "ALXO".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a regulatory listing status rather than periodic financial performance.
Material Changes
On April 23, 2025, the Company received a written notice from the Nasdaq Listing Qualifications Staff indicating non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)). The stock's closing price has remained below $1.00 per share for 30 consecutive business days.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-calendar day compliance period, ending October 20, 2025, to regain compliance.
- Requirements: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period.
- Contingencies: If compliance is not met within the initial period, the Company may be eligible for a second 180-day period if it elects to transfer to the Nasdaq Capital Market and meets other listing standards.
- Delisting Risk: Failure to regain compliance within the allotted periods may result in delisting.
- Management Action: The Company intends to monitor the stock price and assess potential actions, including effecting a reverse stock split, to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of ALXO stock relative to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes.
- Track the Company's progress toward meeting the ten consecutive business day requirement before the October 20, 2025 deadline.
- Review future filings for updates on the Company's intent to transfer to the Nasdaq Capital Market if the initial compliance period is unsuccessful.